Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00889330 · ClinicalTrials.gov registry record · Phase 3
Safety and Efficacy Study of a Eye Drop for Eye Allergy
A Phase 3 study, sponsored by Vistakon Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 60
- Enrollment target
NCT00889330 is a Phase 3 study that has completed, run by Vistakon Pharmaceuticals. The registered enrollment target is 60 participants.
The verdict
NCT00889330, a Phase 3 study, has completed, sponsored by Vistakon Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 60 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the efficacy and safety of an anti-allergy eyedrop.
Interventions
- DRUG Placebo
- DRUG alcaftadine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2009-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00889330
The ClinicalTrials.gov registry entry for NCT00889330 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vistakon Pharmaceuticals, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00889330 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00889330 about?
NCT00889330 is a clinical study titled "Safety and Efficacy Study of a Eye Drop for Eye Allergy". The purpose of this study is to evaluate the efficacy and safety of an anti-allergy eyedrop.
What is the current status of trial NCT00889330?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 60 participants. The study started on 2009-04.
What interventions are being tested in trial NCT00889330?
The interventions under investigation include: Placebo (DRUG), alcaftadine (DRUG).
Who is sponsoring clinical trial NCT00889330?
This trial is sponsored by Vistakon Pharmaceuticals, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.